Lancaster JM - Search Results

1

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

2

An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.

Lancaster JM, Wiseman RW, Berchuck A. Lancaster JM, et al. Obstet Gynecol. 1996 Feb;87(2):306-9. doi: 10.1016/0029-7844(95)00405-X. Obstet Gynecol. 1996. PMID: 8559544

3

BRCA2 mutations in primary breast and ovarian cancers.

Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA. Lancaster JM, et al. Nat Genet. 1996 Jun;13(2):238-40. doi: 10.1038/ng0696-238. Nat Genet. 1996. PMID: 8640235

4

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Among authors: lancaster jm. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

5

Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.

Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Lancaster JM, et al. Mol Carcinog. 1996 Nov;17(3):160-2. doi: 10.1002/(SICI)1098-2744(199611)17:3<160::AID-MC8>3.0.CO;2-J. Mol Carcinog. 1996. PMID: 8944076

6

Dideoxy fingerprinting assay for BRCA1 mutation analysis.

Lancaster JM, Berchuck A, Futreal PA, Wiseman RW. Lancaster JM, et al. Mol Carcinog. 1997 Jul;19(3):176-9. Mol Carcinog. 1997. PMID: 9254884

7

Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.

Berchuck A, Carney M, Lancaster JM, Marks J, Futreal AP. Berchuck A, et al. Among authors: lancaster jm. Clin Obstet Gynecol. 1998 Mar;41(1):157-66. doi: 10.1097/00003081-199803000-00022. Clin Obstet Gynecol. 1998. PMID: 9504233 Review. No abstract available.

8

Progesterone receptor gene polymorphism and risk for breast and ovarian cancer.

Lancaster JM, Berchuck A, Carney ME, Wiseman R, Taylor JA. Lancaster JM, et al. Br J Cancer. 1998 Jul;78(2):277. doi: 10.1038/bjc.1998.480. Br J Cancer. 1998. PMID: 9683307 Free PMC article. No abstract available.

9

Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.

Carney ME, Maxwell GL, Lancaster JM, Gumbs C, Marks J, Berchuck A, Futreal PA. Carney ME, et al. Among authors: lancaster jm. J Soc Gynecol Investig. 1998 Sep-Oct;5(5):281-5. doi: 10.1016/s1071-5576(98)00018-5. J Soc Gynecol Investig. 1998. PMID: 9773405

10

Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS. Berchuck A, et al. Among authors: lancaster jm. Clin Cancer Res. 1998 Oct;4(10):2433-7. Clin Cancer Res. 1998. PMID: 9796975

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters